ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0273

Barriers and Facilitators for Outpatient Follow-Up After an Acute Gout Flare: A Qualitative Research Study

Elizabeth Lopez1, Lesley Jackson2, Kenneth Saag3 and Maria I. ("Maio") Danila4, 1University of Alabama at Birmingham, Montgomery, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3The University of Alabama at Birmingham, Birmingham, AL, 4University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL

Meeting: ACR Convergence 2024

Keywords: Access to care, Disparities, gout, health behaviors, Qualitative Research

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Many people with gout utilize the emergency department (ED) for acute gout care, but many do not receive subsequent adequate outpatient care for long-term gout management. We aimed to identify barriers and facilitators to receiving outpatient follow-up for gout and adherence to outpatient gout treatments to identify potential targets for future interventions.

Methods: We developed a semi-structured interview guide addressing 3 areas of gout care: experience during an ED visit for acute gout, and barriers and facilitators to follow-up and gout medication adherence. We recruited people with a confirmed gout flare at our institution and who did not have an outpatient follow-up for gout within 3-months after the ED visit. We contacted potential participants by phone. Eligible participants were consented for a semi-structured phone interview created using the social ecological framework to examine the interplay between personal and societal influences on gout follow up. Interviews were audio recorded and transcribed using Nvivo and checked for accuracy. Transcripts were coded independently and emerging themes and sub-themes were analyzed using reflexive thematic analysis using NVivo 12.

Results: Twelve individuals mean (SD) age 61 years, 7 (83%) Black or African American were interviewed to reach thematic saturation (Table 1) out of 70 people contacted. Barriers and facilitators were organized into 7 major themes and 22 sub-themes following a social ecological framework (Table 2). Lack of reliable transportation and of an established outpatient clinician were significant barriers to follow-up in 75% and 42% of interviewees. The impact of gout on an individual’s physical function to go to clinic was a barrier for 67% of people, and 33% reported gout having a negative effect on their social life. Facilitators included ED clinician providing information on gout including emphasis on the need to follow up in the outpatient setting (92%), having an established outpatient clinician provider for their gout care (58%), trust in treating clinician (83%), and adhering to a low purine diet (75%). 

Conclusion: Numerous individual and system-level factors influence outpatient gout care and medication adherence. It is crucial that clinicians are aware of common modifiable factors facing this patient population to improve quality of gout care.

Supporting image 1

Supporting image 2


Disclosures: E. Lopez: None; L. Jackson: None; K. Saag: AbbVie/Abbott, 2, Allena, 5, Amgen, 2, 5, arthrosi, 2, 5, atom bioscience, 2, bayer, 2, csl behring, 2, daiichi sankyo, 2, dyve, 5, Gilead, 2, horizon, 2, 5, inflazome, 2, LG chem, 5, LG Pharma, 5, Mallinkrodt, 2, Radius, 2, 5, Roche/ genentech, 2, Shanton, 5, SOBI, 2, 5, Takeda, 2, 5, Ultragenex, 5; M. Danila: AbbVie/Abbott, 2, Pfizer, 5.

To cite this abstract in AMA style:

Lopez E, Jackson L, Saag K, Danila M. Barriers and Facilitators for Outpatient Follow-Up After an Acute Gout Flare: A Qualitative Research Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/barriers-and-facilitators-for-outpatient-follow-up-after-an-acute-gout-flare-a-qualitative-research-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/barriers-and-facilitators-for-outpatient-follow-up-after-an-acute-gout-flare-a-qualitative-research-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology